select a format

Single User License
USD 2000 INR 128080
Site License
USD 4000 INR 256160
Corporate User License
USD 6000 INR 384240

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Acne Vulgaris-Pipeline Review, H2 2015

Acne Vulgaris-Pipeline Review, H2 2015


  • Products Id :- GMDHC7218IDB
  • |
  • Pages: 186
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Acne Vulgaris-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Acne Vulgaris-Pipeline Review, H2 2015', provides an overview of the Acne Vulgaris's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acne Vulgaris and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acne Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Acne Vulgaris Overview 10

Therapeutics Development 11

Pipeline Products for Acne Vulgaris-Overview 11

Pipeline Products for Acne Vulgaris-Comparative Analysis 12

Acne Vulgaris-Therapeutics under Development by Companies 13

Acne Vulgaris-Therapeutics under Investigation by Universities/Institutes 18

Acne Vulgaris-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Acne Vulgaris-Products under Development by Companies 22

Acne Vulgaris-Products under Investigation by Universities/Institutes 26

Acne Vulgaris-Companies Involved in Therapeutics Development 27

3SBio Inc. 27

Advancell 28

Allergan Plc 29

Almirall, S.A. 30

Biomar Microbial Technologies 31

Braintree Laboratories, Inc. 32

Brickell Biotech, Inc. 33

Celtaxsys, Inc. 34

Cosmo Pharmaceuticals S.p.A 35

Delenex Therapeutics AG 36

Deltanoid Pharmaceuticals Inc. 37

DermaXon, LLC 38

Dermira Inc. 39

ELORAC, Inc. 40

Ensol Biosciences Inc. 41

Foamix Pharmaceuticals Ltd. 42

Galderma S.A. 43

GlaxoSmithKline Plc 44

Helix BioMedix, Inc. 45

Hovione FarmaCiencia SA 46

Lee's Pharmaceutical Holdings Limited 47

Maruho Co., Ltd. 48

Novabiotics Limited 49

Novan, Inc. 50

OrigImm e.U. 51

Paratek Pharmaceuticals, Inc. 52

Phosphagenics Limited 53

Photocure ASA 54

Promius Pharma, LLC 55

Provectus Biopharmaceuticals, Inc. 56

RestorGenex Corporation 57

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 58

SkyePharma Plc 59

Telesso Technologies Limited 60

Thesan Pharmaceuticals, Inc. 61

Toyama Chemical Co., Ltd. 62

Valeant Pharmaceuticals International, Inc. 63

Venn Life Sciences Holdings Plc 64

Vyome Biosciences Private Limited 65

Xenon Pharmaceuticals Inc. 66

Acne Vulgaris-Therapeutics Assessment 67

Assessment by Monotherapy Products 67

Assessment by Combination Products 68

Assessment by Target 69

Assessment by Mechanism of Action 72

Assessment by Route of Administration 74

Assessment by Molecule Type 76

Drug Profiles 78

(adapalene + benzoyl peroxide)-Drug Profile 78

(adapalene + clindamycin hydrochloride)-Drug Profile 79

(clindamycin phosphate + tretinoin)-Drug Profile 80

acebilustat-Drug Profile 81

Aczone X-Drug Profile 83

AD-037-Drug Profile 84

aminolevulinic acid hydrochloride-Drug Profile 85

ANs-29-Drug Profile 86

AQ-401-Drug Profile 87

B-244-Drug Profile 88

BBI-3000-Drug Profile 89

becocalcidiol-Drug Profile 90

benzoyl peroxide-Drug Profile 91

benzoyl peroxide-Drug Profile 92

BLI-1100-Drug Profile 93

CB-0301-Drug Profile 94

CB-0604-Drug Profile 96

DFD-10-Drug Profile 97

DLX-2323-Drug Profile 98

DLX-2681-Drug Profile 99

DRM-01-Drug Profile 100

Drugs for Acne-Drug Profile 101

DX-0385-Drug Profile 102

E-10215-Drug Profile 103

finasteride-Drug Profile 104

FMX-101-Drug Profile 105

GSK-1940029-Drug Profile 107

HB-1345-Drug Profile 108

Hesed-4000-Drug Profile 109

IB-07A037-Drug Profile 110

IDP-120-Drug Profile 111

IDP-121-Drug Profile 112

IDP-123-Drug Profile 113

methyl aminolevulinate hydrochloride-Drug Profile 114

minocycline-Drug Profile 116

minocycline-Drug Profile 117

MTC-896-Drug Profile 118

NAI-003-Drug Profile 120

NVN-1000-Drug Profile 121

omiganan pentahydrochloride-Drug Profile 123

onabotulinumtoxin A-Drug Profile 125

ozenoxacin-Drug Profile 127

Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer-Drug Profile 129

PH-10-Drug Profile 130

RES-440-Drug Profile 132

sarecycline hydrochloride-Drug Profile 134

SKP-026-Drug Profile 136

Small Molecule for Acne and Skin Inflammation-Drug Profile 137

SYN-1113-Drug Profile 139

Synthetic Peptide for Acne Vulgaris-Drug Profile 140

Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders-Drug Profile 141

tretinoin-Drug Profile 142

trifarotene-Drug Profile 144

Vaccine for Acne Vulgaris-Drug Profile 145

Vaccine for Acne Vulgaris-Drug Profile 146

VB-1953-Drug Profile 147

XEN-801-Drug Profile 148

Acne Vulgaris-Recent Pipeline Updates 149

Acne Vulgaris-Dormant Projects 163

Acne Vulgaris-Discontinued Products 171

Acne Vulgaris-Product Development Milestones 172

Featured News & Press Releases 172

Appendix 182

Methodology 182

Coverage 182

Secondary Research 182

Primary Research 182

Expert Panel Validation 182

Contact Us 182

Disclaimer 183

List of Tables

Number of Products under Development for Acne Vulgaris, H2 2015 15

Number of Products under Development for Acne Vulgaris-Comparative Analysis, H2 2015 16

Number of Products under Development by Companies, H2 2015 18

Number of Products under Development by Companies, H2 2015 (Contd..1) 19

Number of Products under Development by Companies, H2 2015 (Contd..2) 20

Number of Products under Development by Companies, H2 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H2 2015 22

Comparative Analysis by Late Stage Development, H2 2015 23

Comparative Analysis by Clinical Stage Development, H2 2015 24

Comparative Analysis by Early Stage Development, H2 2015 25

Products under Development by Companies, H2 2015 26

Products under Development by Companies, H2 2015 (Contd..1) 27

Products under Development by Companies, H2 2015 (Contd..2) 28

Products under Development by Companies, H2 2015 (Contd..3) 29

Products under Investigation by Universities/Institutes, H2 2015 30

Acne Vulgaris-Pipeline by 3SBio Inc., H2 2015 31

Acne Vulgaris-Pipeline by Advancell, H2 2015 32

Acne Vulgaris-Pipeline by Allergan Plc, H2 2015 33

Acne Vulgaris-Pipeline by Almirall, S.A., H2 2015 34

Acne Vulgaris-Pipeline by Biomar Microbial Technologies, H2 2015 35

Acne Vulgaris-Pipeline by Braintree Laboratories, Inc., H2 2015 36

Acne Vulgaris-Pipeline by Brickell Biotech, Inc., H2 2015 37

Acne Vulgaris-Pipeline by Celtaxsys, Inc., H2 2015 38

Acne Vulgaris-Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2015 39

Acne Vulgaris-Pipeline by Delenex Therapeutics AG, H2 2015 40

Acne Vulgaris-Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015 41

Acne Vulgaris-Pipeline by DermaXon, LLC, H2 2015 42

Acne Vulgaris-Pipeline by Dermira Inc., H2 2015 43

Acne Vulgaris-Pipeline by ELORAC, Inc., H2 2015 44

Acne Vulgaris-Pipeline by Ensol Biosciences Inc., H2 2015 45

Acne Vulgaris-Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 46

Acne Vulgaris-Pipeline by Galderma S.A., H2 2015 47

Acne Vulgaris-Pipeline by GlaxoSmithKline Plc, H2 2015 48

Acne Vulgaris-Pipeline by Helix BioMedix, Inc., H2 2015 49

Acne Vulgaris-Pipeline by Hovione FarmaCiencia SA, H2 2015 50

Acne Vulgaris-Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 51

Acne Vulgaris-Pipeline by Maruho Co., Ltd., H2 2015 52

Acne Vulgaris-Pipeline by Novabiotics Limited, H2 2015 53

Acne Vulgaris-Pipeline by Novan, Inc., H2 2015 54

Acne Vulgaris-Pipeline by OrigImm e.U., H2 2015 55

Acne Vulgaris-Pipeline by Paratek Pharmaceuticals, Inc., H2 2015 56

Acne Vulgaris-Pipeline by Phosphagenics Limited, H2 2015 57

Acne Vulgaris-Pipeline by Photocure ASA, H2 2015 58

Acne Vulgaris-Pipeline by Promius Pharma, LLC, H2 2015 59

Acne Vulgaris-Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015 60

Acne Vulgaris-Pipeline by RestorGenex Corporation, H2 2015 61

Acne Vulgaris-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015 62

Acne Vulgaris-Pipeline by SkyePharma Plc, H2 2015 63

Acne Vulgaris-Pipeline by Telesso Technologies Limited, H2 2015 64

Acne Vulgaris-Pipeline by Thesan Pharmaceuticals, Inc., H2 2015 65

Acne Vulgaris-Pipeline by Toyama Chemical Co., Ltd., H2 2015 66

Acne Vulgaris-Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 67

Acne Vulgaris-Pipeline by Venn Life Sciences Holdings Plc, H2 2015 68

Acne Vulgaris-Pipeline by Vyome Biosciences Private Limited, H2 2015 69

Acne Vulgaris-Pipeline by Xenon Pharmaceuticals Inc., H2 2015 70

Assessment by Monotherapy Products, H2 2015 71

Assessment by Combination Products, H2 2015 72

Number of Products by Stage and Target, H2 2015 74

Number of Products by Stage and Mechanism of Action, H2 2015 77

Number of Products by Stage and Route of Administration, H2 2015 79

Number of Products by Stage and Molecule Type, H2 2015 81

Acne Vulgaris Therapeutics-Recent Pipeline Updates, H2 2015 152

Acne Vulgaris-Dormant Projects, H2 2015 166

Acne Vulgaris-Dormant Projects (Contd..1), H2 2015 167

Acne Vulgaris-Dormant Projects (Contd..2), H2 2015 168

Acne Vulgaris-Dormant Projects (Contd..3), H2 2015 169

Acne Vulgaris-Dormant Projects (Contd..4), H2 2015 170

Acne Vulgaris-Dormant Projects (Contd..5), H2 2015 171

Acne Vulgaris-Dormant Projects (Contd..6), H2 2015 172

Acne Vulgaris-Dormant Projects (Contd..7), H2 2015 173

Acne Vulgaris-Discontinued Products, H2 2015 174

List of Figures

Number of Products under Development for Acne Vulgaris, H2 2015 15

Number of Products under Development for Acne Vulgaris-Comparative Analysis, H2 2015 16

Number of Products under Development by Companies, H2 2015 17

Number of Products under Investigation by Universities/Institutes, H2 2015 22

Comparative Analysis by Late Stage Development, H2 2015 23

Comparative Analysis by Clinical Stage Development, H2 2015 24

Comparative Analysis by Early Stage Products, H2 2015 25

Assessment by Monotherapy Products, H2 2015 71

Assessment by Combination Products, H2 2015 72

Number of Products by Top 10 Targets, H2 2015 73

Number of Products by Stage and Top 10 Targets, H2 2015 73

Number of Products by Top 10 Mechanism of Actions, H2 2015 76

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 76

Number of Products by Routes of Administration, H2 2015 78

Number of Products by Stage and Routes of Administration, H2 2015 78

Number of Products by Molecule Types, H2 2015 80

Number of Products by Stage and Molecule Types, H2 2015 80

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc.

Advancell

Allergan Plc

Almirall, S.A.

Biomar Microbial Technologies

Braintree Laboratories, Inc.

Brickell Biotech, Inc.

Celtaxsys, Inc.

Cosmo Pharmaceuticals S.p.A

Delenex Therapeutics AG

Deltanoid Pharmaceuticals Inc.

DermaXon, LLC

Dermira Inc.

ELORAC, Inc.

Ensol Biosciences Inc.

Foamix Pharmaceuticals Ltd.

Galderma S.A.

GlaxoSmithKline Plc

Helix BioMedix, Inc.

Hovione FarmaCiencia SA

Lee's Pharmaceutical Holdings Limited

Maruho Co., Ltd.

Novabiotics Limited

Novan, Inc.

OrigImm e.U.

Paratek Pharmaceuticals, Inc.

Phosphagenics Limited

Photocure ASA

Promius Pharma, LLC

Provectus Biopharmaceuticals, Inc.

RestorGenex Corporation

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

SkyePharma Plc

Telesso Technologies Limited

Thesan Pharmaceuticals, Inc.

Toyama Chemical Co., Ltd.

Valeant Pharmaceuticals International, Inc.

Venn Life Sciences Holdings Plc

Vyome Biosciences Private Limited

Xenon Pharmaceuticals Inc.

Acne Vulgaris Therapeutic Products under Development, Key Players in Acne Vulgaris Therapeutics, Acne Vulgaris Pipeline Overview, Acne Vulgaris Pipeline, Acne Vulgaris Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com